Ignite Creation Date:
2024-05-06 @ 3:27 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02291237
Status:
TERMINATED
Last Update Posted:
2018-09-24
First Post:
2014-11-11
Brief Title:
Effect of Eleclazine GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
Study Title A Phase 23 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status:
TERMINATED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LIBERTY-HCM
Brief Summary:
The primary objective of this study was to evaluate the effect of eleclazine GS-6615 on exercise capacity as measured by Peak oxygen uptake VO2 achieved during cardiopulmonary exercise testing CPET in participants with symptomatic hypertrophic cardiomyopathy HCM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-004429-97 | EUDRACT_NUMBER | None | None |